MedTrace Logo

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

NCT04774406 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2336

Last updated 2023-06-06

No results posted yet for this study

Summary

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce.

The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Conditions

Interventions

DRUG

olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib

All patients treated at least with 1 PARPi (alone or in combination)

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-24
Primary Completion
2021-05-09
Completion
2022-09-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04774406 on ClinicalTrials.gov